-transparent.png){kind=logo}
In a 6-week clinical trial 4 dose regimens of 3'-azido-3'-deoxythymidine (AZT), a thymidine analogue with potent anti-viral activity against HTLV-III in vitro, were examined in 19 patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC). AZT was given intravenously for 2 weeks, then orally for 4 weeks at twice the intravenous dose. AZT was well absorbed from the gut and crossed the blood-brain barrier. Therapeutic levels were maintained with 5 mg given intravenously or 10 mg given orally every 4 h. Treatment was not limited by side-effects, the commonest of which were headaches and depression of white-cell counts. 15 of the 19 patients had increases in their numbers of circulating helper-inducer T lymphocytes (p less than 0.001) during therapy, 6 who were anergic at entry showed positive delayed type hypersensitivity skin test reactions during treatment, 2 had clearance of chronic fungal nailbed infections without specific anti-fungal therapy, 6 had other evidence of clinical improvement, and the group as a whole had a weight gain of 2.2 kg. Also, with the highest dose regimen cultures of peripheral blood mononuclear cells for HTLV III became negative.
R Yarchoan, and
R W Klecker, and
K J Weinhold, and
P D Markham, and
H K Lyerly, and
D T Durack, and
E Gelmann, and
S N Lehrman, and
R M Blum, and
D W Barry
February 1986,
The New England journal of medicine,
R Yarchoan, and
R W Klecker, and
K J Weinhold, and
P D Markham, and
H K Lyerly, and
D T Durack, and
E Gelmann, and
S N Lehrman, and
R M Blum, and
D W Barry
July 1986,
Quintessenz Journal,
R Yarchoan, and
R W Klecker, and
K J Weinhold, and
P D Markham, and
H K Lyerly, and
D T Durack, and
E Gelmann, and
S N Lehrman, and
R M Blum, and
D W Barry
January 1986,
Pennsylvania medicine,
R Yarchoan, and
R W Klecker, and
K J Weinhold, and
P D Markham, and
H K Lyerly, and
D T Durack, and
E Gelmann, and
S N Lehrman, and
R M Blum, and
D W Barry
May 1986,
British medical journal (Clinical research ed.),
R Yarchoan, and
R W Klecker, and
K J Weinhold, and
P D Markham, and
H K Lyerly, and
D T Durack, and
E Gelmann, and
S N Lehrman, and
R M Blum, and
D W Barry
October 1985,
JAMA,
R Yarchoan, and
R W Klecker, and
K J Weinhold, and
P D Markham, and
H K Lyerly, and
D T Durack, and
E Gelmann, and
S N Lehrman, and
R M Blum, and
D W Barry
January 1986,
Japanese journal of cancer research : Gann,
R Yarchoan, and
R W Klecker, and
K J Weinhold, and
P D Markham, and
H K Lyerly, and
D T Durack, and
E Gelmann, and
S N Lehrman, and
R M Blum, and
D W Barry
January 1987,
AIDS research and human retroviruses,
R Yarchoan, and
R W Klecker, and
K J Weinhold, and
P D Markham, and
H K Lyerly, and
D T Durack, and
E Gelmann, and
S N Lehrman, and
R M Blum, and
D W Barry
January 1987,
Acta pathologica, microbiologica, et immunologica Scandinavica. Section A, Pathology,
R Yarchoan, and
R W Klecker, and
K J Weinhold, and
P D Markham, and
H K Lyerly, and
D T Durack, and
E Gelmann, and
S N Lehrman, and
R M Blum, and
D W Barry
January 1993,
The Journal of infectious diseases,
R Yarchoan, and
R W Klecker, and
K J Weinhold, and
P D Markham, and
H K Lyerly, and
D T Durack, and
E Gelmann, and
S N Lehrman, and
R M Blum, and
D W Barry
June 1986,
Science (New York, N.Y.),
